Urology Practice Management - December 2016, Vol 5, No 6

From 2007 to 2013, the incidence of metastatic prostate cancer increased by 7.1% annually, resulting in a cumulative increase of 72% compared with 2004. Read More ›

The investigational oral androgen receptor drug ODM-201 has significant antitumor activity with a favorable safety profile in men with metastatic castration-resistant prostate cancer, according to a pooled analysis of 2 early-phase clinical trials. Read More ›

The first randomized trial to compare robotic-assisted prostatectomy with conventional open radical prostatectomy found no meaningful differences between these techniques in urinary and sexual function or in the rate of positive surgical margins in men with localized prostate cancer in the first 12 weeks after surgery (Yaxley JW, et al. Lancet. Read More ›

During residency and fellowship, physicians are focused on their clinical responsibilities and often lack the time or the inclination to concern themselves with financial issues, such as managing debt, creating a budget, obtaining necessary insurance protection, or contributing to retirement plans. Read More ›